Prognostic effect of hENT1, dCK and HuR expression by morphological type in periampullary adenocarcinoma, including pancreatic cancer.

Jacob Elebro; Liv Ben Dror; Margareta Heby; Björn Nodin; Karin Jirström; Jakob Eberhard

doi:10.3109/0284186X.2015.1075663

Prognostic effect of hENT1, dCK and HuR expression by morphological type in periampullary adenocarcinoma, including pancreatic cancer.

Jacob Elebro, Liv Ben Dror, Margareta Heby, Björn Nodin, Karin Jirström, Jakob Eberhard

Tumor microenvironment

Research output: Contribution to journal › Article › peer-review

Abstract

Putative biomarkers of gemcitabine response have been extensively studied in pancreatic cancer, but less so in other types of periampullary adenocarcinoma. The most studied biomarker is human equilibrative nucleoside transporter 1 (hENT1), and the activating enzyme deoxycytidine kinase (dCK) has also been linked to treatment response. The RNA-binding protein human antigen R (HuR) has been demonstrated to confer increased dCK levels in vitro and to predict gemcitabine response in vivo. Here, we investigated the prognostic impact of hENT1, dCK and HuR in pancreatobiliary (PB) and intestinal (I) type periampullary cancers, respectively.

Original language	English
Pages (from-to)	286-96
Journal	Acta oncologica (Stockholm, Sweden)
Volume	55
Issue number	3
Early online date	2015
DOIs	https://doi.org/10.3109/0284186X.2015.1075663
Publication status	Published - 2016

Subject classification (UKÄ)

Cancer and Oncology

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.3109/0284186X.2015.1075663

1 Doctoral Thesis (compilation)

Prognostic factors in periampullary adenocarcinoma. A retrospective study over an 11 year period.
Elebro, J., 2016, Lund: Lund University: Faculty of Medicine. 83 p.
Research output: Thesis › Doctoral Thesis (compilation)

Open Access
File

Cite this

@article{3c0991e86c2d4184b5527d3f94b1e086,

title = "Prognostic effect of hENT1, dCK and HuR expression by morphological type in periampullary adenocarcinoma, including pancreatic cancer.",

abstract = "Putative biomarkers of gemcitabine response have been extensively studied in pancreatic cancer, but less so in other types of periampullary adenocarcinoma. The most studied biomarker is human equilibrative nucleoside transporter 1 (hENT1), and the activating enzyme deoxycytidine kinase (dCK) has also been linked to treatment response. The RNA-binding protein human antigen R (HuR) has been demonstrated to confer increased dCK levels in vitro and to predict gemcitabine response in vivo. Here, we investigated the prognostic impact of hENT1, dCK and HuR in pancreatobiliary (PB) and intestinal (I) type periampullary cancers, respectively.",

author = "Jacob Elebro and {Ben Dror}, Liv and Margareta Heby and Bj{\"o}rn Nodin and Karin Jirstr{\"o}m and Jakob Eberhard",

year = "2016",

doi = "10.3109/0284186X.2015.1075663",

language = "English",

volume = "55",

pages = "286--96",

journal = "Acta oncologica (Stockholm, Sweden)",

issn = "1651-226X",

publisher = "Taylor & Francis",

number = "3",

}

TY - JOUR

T1 - Prognostic effect of hENT1, dCK and HuR expression by morphological type in periampullary adenocarcinoma, including pancreatic cancer.

AU - Elebro, Jacob

AU - Ben Dror, Liv

AU - Heby, Margareta

AU - Nodin, Björn

AU - Jirström, Karin

AU - Eberhard, Jakob

PY - 2016

Y1 - 2016

N2 - Putative biomarkers of gemcitabine response have been extensively studied in pancreatic cancer, but less so in other types of periampullary adenocarcinoma. The most studied biomarker is human equilibrative nucleoside transporter 1 (hENT1), and the activating enzyme deoxycytidine kinase (dCK) has also been linked to treatment response. The RNA-binding protein human antigen R (HuR) has been demonstrated to confer increased dCK levels in vitro and to predict gemcitabine response in vivo. Here, we investigated the prognostic impact of hENT1, dCK and HuR in pancreatobiliary (PB) and intestinal (I) type periampullary cancers, respectively.

AB - Putative biomarkers of gemcitabine response have been extensively studied in pancreatic cancer, but less so in other types of periampullary adenocarcinoma. The most studied biomarker is human equilibrative nucleoside transporter 1 (hENT1), and the activating enzyme deoxycytidine kinase (dCK) has also been linked to treatment response. The RNA-binding protein human antigen R (HuR) has been demonstrated to confer increased dCK levels in vitro and to predict gemcitabine response in vivo. Here, we investigated the prognostic impact of hENT1, dCK and HuR in pancreatobiliary (PB) and intestinal (I) type periampullary cancers, respectively.

U2 - 10.3109/0284186X.2015.1075663

DO - 10.3109/0284186X.2015.1075663

M3 - Article

C2 - 26362587

SN - 1651-226X

VL - 55

SP - 286

EP - 296

JO - Acta oncologica (Stockholm, Sweden)

JF - Acta oncologica (Stockholm, Sweden)

IS - 3

ER -

Prognostic effect of hENT1, dCK and HuR expression by morphological type in periampullary adenocarcinoma, including pancreatic cancer.

Abstract

Subject classification (UKÄ)

UN SDGs

Access to Document

Fingerprint

Research output

Prognostic factors in periampullary adenocarcinoma. A retrospective study over an 11 year period.

Cite this